119 related articles for article (PubMed ID: 34131632)
1. COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment.
Clerico M; Dogliotti I; Calcagno A; Grimaldi D; Leone S; Ragaini S; Boffini M; Caracciolo D; Ferrero S; Barbero C; Zanotto E; Stroffolini G; Cavallo R; Rinaldi M; Bruno B; Cavallo F
Hemasphere; 2021 Jul; 5(7):e592. PubMed ID: 34131632
[No Abstract] [Full Text] [Related]
2. Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report.
Windpessl M; Burgstaller S; Kronbichler A; Pieringer H; Kalev O; Karrer A; Wallner M; Thaler J
Transplant Proc; 2018 Apr; 50(3):881-883. PubMed ID: 29661457
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era.
Tamjid B; Mckendrick J; Schwarer A; Doig R; James P; Hosking P; Hawkes EA
Asia Pac J Clin Oncol; 2017 Jun; 13(3):226-233. PubMed ID: 28004881
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant lymphoproliferative disorder presenting with skin ulceration in a renal transplant recipient who achieved sustained remission with rituximab therapy: A case report.
Law MF; Chan HN; Lai HK; Ha CY; Ng C; Yeung YM; Yip SF
Mol Clin Oncol; 2016 Nov; 5(5):610-612. PubMed ID: 27900097
[TBL] [Abstract][Full Text] [Related]
6. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
7. Long-term remission in an adult heart transplant recipient with advanced Burkitt's lymphoma post-transplant lymphoproliferative disorder after anthracycline-free chemotherapy: A case report and literature review.
AbdelHameid D; Felice A; Cooper LB; Katugaha SB
Transpl Infect Dis; 2020 Aug; 22(4):e13265. PubMed ID: 32077552
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
9. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disease after liver transplantation.
Herrero JI; Panizo C
Rev Esp Enferm Dig; 2018 Feb; 110(2):131-132. PubMed ID: 29313699
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1S2):56-69. PubMed ID: 28140093
[TBL] [Abstract][Full Text] [Related]
13. Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child.
Bueno J; Ramil C; Somoza I; Sanchez-Galindo A; Solar A; Arnal F; Alvarez A; Sánchez-Mozo P; Gómez M
Pediatr Transplant; 2003 Apr; 7(2):153-6. PubMed ID: 12654058
[TBL] [Abstract][Full Text] [Related]
14. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.
Shimoni A; Hardan I; Avigdor A; Yeshurun M; Raanani P; Ben-Bassat I; Nagler A
Br J Haematol; 2003 Aug; 122(3):457-64. PubMed ID: 12877674
[TBL] [Abstract][Full Text] [Related]
15. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
16. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G
Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
[TBL] [Abstract][Full Text] [Related]
19. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
20. A family cluster of diagnosed coronavirus disease 2019 (COVID-19) kidney transplant recipient in Thailand.
Sakulkonkij P; Bruminhent J; Pankongngam C; Chalermphunchai N
Immun Inflamm Dis; 2020 Dec; 8(4):534-543. PubMed ID: 32770646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]